Hepatocytic lipocalin-2 controls HDL metabolism and atherosclerosis via Nedd4-1-SR-BI axis in mice

High-density lipoprotein (HDL) metabolism is regulated by complex interplay between the scavenger receptor group B type 1 (SR-BI) and multiple signaling molecules in the liver. Here, we show that lipocalin-2 (Lcn2) is a key regulator of hepatic SR-BI, HDL metabolism, and atherosclerosis. Overexpression of human Lcn2 in hepatocytes attenuates the development of atherosclerosis via SR-BI in western-diet-fed Ldlr(-/-) mice, whereas hepatocyte-specific ablation of Lcn2 has the opposite effect. Mechanistically, hepatocyte Lcn2 improves HDLmetabolism and alleviates atherogenesis by blocking Nedd4-1- mediated SR-BI ubiquitination at K500 and K508. The Lcn2-improved HDL metabolism is abolished in mice with hepatocyte-specific Nedd4-1 or SR-BI deletion and in SR-BI (K500A/K508A) mutation mice. This study identifies a regulatory axis from Lcn2 to HDL via blocking Nedd4-1-mediated SR-BI ubiquitination and demonstrates that hepatocyte Lcn2 may be a promising target to improve HDL metabolism to treat atherosclerotic cardiovascular diseases.

Automated summary

This study identifies lipocalin-2 (Lcn2) as a key regulator of hepatic scavenger receptor group B type 1 (SR-BI) and high-density lipoprotein (HDL) metabolism, and its role in atherosclerosis. Lcn2 improves HDL metabolism and alleviates atherogenesis by inhibiting Nedd4-1-mediated SR-BI ubiquitination at specific sites. Hepatocyte Lcn2 may be a promising target for improving HDL metabolism and treating atherosclerotic cardiovascular diseases.